Basetrophy Group Holdings Limited (Basetrophy GP) has filed its statutory Monthly Return for the period ended 31 May 2026, confirming stable capital metrics and adherence to Hong Kong Stock Exchange public-float rules.
Authorised capital remained unchanged at 3.00 billion ordinary shares with a par value of HKD 0.10 each, keeping total authorised share capital at HKD 300.00 million.
Issued share capital was steady at 265.61 million ordinary shares, and the company reported no treasury shares on hand or in movement during the month. Consequently, total issued shares likewise held at 265.61 million.
The company affirmed that it continued to satisfy the exchange’s minimum 25 percent public-float requirement as of 31 May 2026.
No activity occurred under the 7 June 2017 Share Option Scheme, and there were no warrants, convertible instruments, or other equity-linked agreements outstanding or exercised.
These disclosures indicate a month of no equity dilution or capital restructuring for Basetrophy GP, with governance confirmations signed by Co-Chairman and Executive Director Mr Chan Kui Ming on 1 June 2026.
Comments